CA
NZ
UK
AU
IND
US
● A year earlier net earnings were roughly $1.083 billion, or $4.20 a share.
● The Apogee TherapeuticsAcquisitionclosed, adding antibodies for atopic dermatitis and asthma.
● Large acquired research charges weighed on reported and adjusted earnings.
● The meeting was adjourned in September for lack of quorum and reconvened in late October.
● Cash and deposits stood above $800 million.
● The board grows from 10 to 11 members, so the seat is new.
● Last quarter sales grew and guidance rose, yet reportedEarningscollapsed on a talc-related charge.
● Reported EPS guidance fell because of acquired research charges from the AtaiBeckley and Curevo deals.
● Ohtuvayre came to Merck through theAcquisitionof Verona Pharma.
● A non-cashImpairmentof roughly C$52 million hit Cannabis Operations, and a strategic review began.
Please wait processing your request...